Special Lecture
Modulation of T cell responses by IL-2 and IL-2 complexes
O. Boyman1, A.G. Kolios2, M.E. Räber3
- Department of Immunology, University Hospital Zurich, University of Zurich, Switzerland. onur.boyman@uzh.ch
- Department of Immunology, University Hospital Zurich, University of Zurich, Switzerland.
- Department of Immunology, University Hospital Zurich, University of Zurich, Switzerland.
CER8904
2015 Vol.33, N°4 ,Suppl.92
PI 0054, PF 0057
Special Lecture
Free to view
(click on article PDF icon to read the article)
PMID: 26457438 [PubMed]
Received: 28/08/2015
Accepted : 01/09/2015
In Press: 12/10/2015
Published: 14/10/2015
Abstract
Interleukin-2 (IL-2) is a cytokine centrally involved in the regulation of immune tolerance and activation by its effects on CD4+ T regulatory (Treg) cells and cytotoxic effector lymphocytes, respectively. Due to these properties IL-2 immunotherapy has been used, as low-dose IL-2, in the treatment of autoimmune and chronic-inflammatory disorders; conversely, at high doses, IL-2 has shown efficacy in a subset of patients with metastatic cancer. Recent advances have highlighted the possibility of using improved IL-2-based therapies, such IL-2-antibody complexes (IL-2 complexes), able to selectively and potently stimulate either Treg cells or cytotoxic effector cells. This article discusses the properties and clinical implications of IL-2 and IL-2 complexes.
